NuCana (NCNA) Liabilities and Shareholders Equity (2016 - 2025)
NuCana (NCNA) reported Liabilities and Shareholders Equity of $39.7 million for Q4 2025, up 109.28% on a YoY basis from $19.0 million in Q4 2024, and down 8.99% sequentially from $43.6 million in Q3 2025.
NuCana (NCNA) Liabilities and Shareholders Equity (2016 - 2025) Analysis & Trends
NuCana (NCNA) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $39.7 million in Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 109.28% year-over-year to $39.7 million; the trailing twelve-month figure through Dec 2025 stood at $119.5 million (up 18.19% YoY), and the FY2025 full-year result was $39.3 million, up 108.29% from the prior year.
- Liabilities and Shareholders Equity slipped to $39.7 million in Q4 2025, from $43.6 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $139.1 million in Q1 2021 to a low of $14.6 million in Q1 2025.
- A 5-year average of $61.7 million and a median of $47.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Peak annual rise in Liabilities and Shareholders Equity reached 109.28% in 2025, while the deepest fall reached 53.56% in 2025.
- Tracing NCNA's Liabilities and Shareholders Equity over 5 years: stood at $104.4 million in 2021, then slumped by 34.57% to $68.3 million in 2022, then plunged by 49.48% to $34.5 million in 2023, then sank by 45.06% to $19.0 million in 2024, then surged by 109.28% to $39.7 million in 2025.
- Business Quant data shows NCNA's Liabilities and Shareholders Equity at $39.7 million in Q4 2025, $43.6 million in Q3 2025, and $21.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 39.68 Mn |
| Sep 30, 2025 | 43.60 Mn |
| Jun 30, 2025 | 21.64 Mn |
| Mar 31, 2025 | 14.61 Mn |
| Dec 31, 2024 | 18.96 Mn |
| Sep 30, 2024 | 25.38 Mn |
| Jun 30, 2024 | 25.33 Mn |
| Mar 31, 2024 | 31.46 Mn |
| Dec 31, 2023 | 34.52 Mn |
| Sep 30, 2023 | 43.03 Mn |
| Jun 30, 2023 | 51.63 Mn |
| Mar 31, 2023 | 59.26 Mn |
| Dec 31, 2022 | 68.33 Mn |
| Sep 30, 2022 | 80.92 Mn |
| Jun 30, 2022 | 83.91 Mn |
| Mar 31, 2022 | 95.84 Mn |
| Dec 31, 2021 | 104.44 Mn |
| Sep 30, 2021 | 123.78 Mn |
| Jun 30, 2021 | 129.04 Mn |
| Mar 31, 2021 | 139.09 Mn |